Compare LTBR & ACOG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LTBR | ACOG |
|---|---|---|
| Founded | 1992 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Professional Services | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 198.7M | 193.6M |
| IPO Year | 2015 | 2024 |
| Metric | LTBR | ACOG |
|---|---|---|
| Price | $5.08 | $8.29 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $18.00 |
| AVG Volume (30 Days) | ★ 640.8K | 88.2K |
| Earning Date | 11-02-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 41.58 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $10,220,275.00 |
| Revenue This Year | N/A | $153.87 |
| Revenue Next Year | N/A | $85.66 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.87 | $4.50 |
| 52 Week High | $28.44 | $10.14 |
| Indicator | LTBR | ACOG |
|---|---|---|
| Relative Strength Index (RSI) | 33.45 | 41.03 |
| Support Level | $4.87 | $8.30 |
| Resistance Level | $7.04 | $9.48 |
| Average True Range (ATR) | 0.34 | 0.43 |
| MACD | -0.03 | -0.05 |
| Stochastic Oscillator | 8.75 | 21.29 |
Lightbridge Corp is a United States-based nuclear fuel technology company. The business activity of the firm is functioned through one business segment, engaged in research and development and commercialization of its nuclear fuel. The Nuclear Fuel Technology segment develops next generation nuclear fuel technology that increases the power output of commercial reactors and reduces the cost of generating electricity. Geographically, its operations are functioned through the region of Unites States.
Alpha Cognition Inc is a biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimers disease, for which there are limited or no treatment options. The Companies current focus is on the commercial manufacturing and sales of ZUNVEYL oral tablet formulation. The Companies commercial development program for ZUNVEYL is focused on building a long-term care commercial team that can focus on providing key points of differentiation, exploiting key issues with existing Acetylcholinesterase inhibitors treatments, and seeking potential licensing partners for other additional indications and new formulations.